pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Antibody-Drug Conjugate (ADC) · news · pharmadog
← back to Antibody-Drug Conjugate (ADC)
News · Antibody-Drug Conjugate (ADC)
162
stories
11h
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
fiercebiotech
3d
Foghorn cuts 40% of workforce
biospace
3d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
5d
Webinar: From Facility to Delivery: Solving the Complex Science of ADC Linker-Payload Synthesis
biospace
6d
AstraZeneca scales Summit’s PD-1xVEGF strategy with $2B investment to fuel ADC combos
fiercebiotech
7d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
7d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
7d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
7d
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
endpoints
7d
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
fiercebiotech
7d
Recon: FDA approves drugs for Parkinson’s, bile duct cancer, rare soft tissue disease; Merck, Daiichi scrap application for ADC ...
raps
10d
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
fiercebiotech
11d
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
13d
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
fiercebiotech
17d
BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data
fiercebiotech
19d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
21d
Summit, BioNTech, more headline WCLC with next-gen lung cancer drugs
biospace
21d
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
fiercebiotech
24d
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
fiercebiotech
25d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
25d
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
27d
4 CDMOs to consider when outsourcing manufacturing
biospace
Sep 4, 26
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
biopharma dive
Sep 4, 26
Pfizer punts Seagen ADC, further muddying value of the $43B buyout
biospace
Sep 3, 26
Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data
endpoints
Sep 3, 26
Pfizer offloads scrapped Seagen ADC to Medicus Pharma in up to $1B+ deal
fiercebiotech
Sep 1, 26
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
fiercebiotech
Aug 28, 26
Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBio
biospace
Aug 28, 26
Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance
endpoints
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
← prev
page 1 of 6
next →
